An unusually high volume of out-of-the-money (OTM) put options in Edwards Lifesciences (EW), which makes heart valve replacement products, shows investors are bullish on EW stock over the next three months. Moreover, EW is below analysts' price targets.
EW is up slightly at $90.78 in midday trading today. It has rebounded significantly since bottoming out right after its July 23 Q2 earnings release. EW hit a recent low of $82.63 on July 24.
More News from Barchart
-
Despite Impressive Results, Nvidia Stock May Be Stuck in a Range - What's the Best Play?
-
Micron Technology Stock Finally Looks Like a Contrarian Opportunity
This may have been a familiar case of "sell on the news." In fact, Edwards Lifesciences produced strong earnings, and management raised its earnings per share (EPS) guidance for 2026.
In fact, EW is still trading well below its average forward price/earnings ratio (see below). That makes today's unusual OTM put volume a signal that investors are likely bullish on EW.
Unusual Put Options Volume
This can be seen in today's Barchart Unusual Stock Options Activity Report. Puts expiring in 81 days on Nov. 20 have been traded in over 25 times the volume of the prior number of contracts outstanding.
There have been almost 2,700 put contracts traded at the $77.50 put strike price, which is almost 15% below today's price (i.e., -14.6% out-of-the-money). Moreover, the premium is still high at 90 cents despite that low strike and extended time period.
That means that an investor(s) who shorted these puts, after posting $7,750 in collateral per contract, immediately receives $90. This works out to a 1.16% yield for the next three months.
More importantly, the breakeven potential buy-in point is $76.60 (i.e., 15.6% lower than today's price). But that only occurs if EW stock drops to $77.50 on or before Nov. 20.
This is even lower than EW's low point on July 24. The point is that this is a very conservative way for an investor to set a value buy-in point and get paid while waiting.
Often, when this occurs, it's a sign that an existing investor is looking to lower their average cost and still make income on their existing holdings.
They may believe that EW stock could be undervalued here. Here's why.
Higher EW Price Targets
Edwards Lifesciences' Q2 revenue was up 13.6% YoY. That was higher than analysts' expectations, according to Seeking Alpha. Moreover, the company posted adj. EPS of 78 cents, up 16.4% from last year's adj. EPS of 67 cents.
Facts Only
* Edwards Lifesciences (EW) stock was trading at $90.78 in midday trading.
* EW hit a recent low of $82.63 on July 24.
* Edwards Lifesciences produced strong earnings.
* Management raised earnings per share (EPS) guidance for 2026.
* Edwards Lifesciences' Q2 revenue was up 13.6% year-over-year (YoY).
* The company posted adjusted EPS of 78 cents, an increase from last year's adjusted EPS of 67 cents.
* Put options expiring in 81 days on November 20 were traded over 25 times the volume of prior contracts outstanding.
* Almost 2,700 put contracts were traded at the $77.50 put strike price.
* The premium for these puts was 90 cents despite the low strike and extended time period.
* The breakeven potential buy-in point for the short position is $76.60, contingent on EW stock dropping to $77.50 by November 20.
Executive Summary
Investors are showing bullish sentiment toward Edwards Lifesciences (EW) over the next three months, evidenced by an unusually high volume of out-of-the-money (OTM) put options. This activity occurs despite the company posting strong earnings and management raising its 2026 EPS guidance. EW is currently trading below its average forward price/earnings ratio, which supports the signal that the option trading reflects a belief that the stock may be undervalued.
The unusual put volume involves contracts expiring in 81 days and at a strike price significantly below the current market price, suggesting a potential income opportunity for short sellers. The breakeven buy-in point for this short position is set relatively low, contingent on the stock price falling to $77.50 by the option expiration date. Furthermore, the company reported strong Q2 revenue growth and an increase in adjusted earnings per share compared to the previous year's figures.
Full Take
The narrative centers on a divergence between reported positive financial results and market positioning indicated by derivative activity. The high volume of OTM puts suggests that some market participants are attempting to bet on a significant downward correction, despite the company's operational strength reflected in its earnings reports. This dynamic creates a tension: fundamental performance suggests stability or upward potential, while options trading signals bearish expectations priced in, potentially exploiting current valuations.
The existence of a low breakeven point ($76.60) for short positions highlights an attempt to establish a protective entry point based on the implied probability of a sharp decline. This structure implies that those with short exposure are seeking maximum potential gain from any subsequent downside movement while simultaneously defining a risk-adjusted entry strategy. The pattern points toward institutional positioning attempting to define risk boundaries rather than reflecting a consensus view of intrinsic value.
The underlying assumption being tested is whether current valuation adequately reflects future growth given strong recent performance. If the OTM put trading reflects genuine fear or mispricing, the market is reacting to a specific expectation that diverges from the positive earnings context. The implication for an observer is recognizing that option volume can be a sophisticated signal of hedging or positioning, requiring separation between operational facts and speculative financial instruments.
Bridge Questions: What is the historical correlation between OTM put volume spikes in high-growth medical device sectors and subsequent earnings revisions? How do the short positions implied by this data correlate with the reported analyst price targets? What external macroeconomic factors might be driving a specific bearish sentiment toward heart valve replacement technology, independent of company performance?
Sentinel — Human
The text appears to be human-written financial commentary synthesizing specific options data and company earnings context to build an argument about stock valuation.